Preclinical tumor mouse models for studying esophageal cancer.


Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 10 05 2023
revised: 13 07 2023
accepted: 14 07 2023
medline: 15 8 2023
pubmed: 20 7 2023
entrez: 19 7 2023
Statut: ppublish

Résumé

Preclinical models are extensively employed in cancer research because they can be manipulated in terms of their environment, genome, molecular biology, organ systems, and physical activity to mimic human behavior and conditions. The progress made in in vivo cancer research has resulted in significant advancements, enabling the creation of spontaneous, metastatic, and humanized mouse models. Most recently, the remarkable and extensive developments in genetic engineering, particularly the utilization of CRISPR/Cas9, transposable elements, epigenome modifications, and liquid biopsies, have further facilitated the design and development of numerous mouse models for studying cancer. In this review, we have elucidated the production and usage of current mouse models, such as xenografts, chemical-induced models, and genetically engineered mouse models (GEMMs), for studying esophageal cancer. Additionally, we have briefly discussed various gene-editing tools that could potentially be employed in the future to create mouse models specifically for esophageal cancer research.

Identifiants

pubmed: 37468084
pii: S1040-8428(23)00156-7
doi: 10.1016/j.critrevonc.2023.104068
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104068

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Auteurs

Reihaneh Alsadat Mahmoudian (RA)

Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Moein Farshchian (M)

Division of Oncology, Laboratory of Cellular Therapy, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia, Modena, Italy.

Fatemeh Fardi Golyan (FF)

Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Parvaneh Mahmoudian (P)

Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Ali Alasti (A)

Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Vahid Moghimi (V)

Department of Biology, Faculty of Science, Hakim Sabzevari University, Sabzevar, Iran.

Mina Maftooh (M)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Majid Khazaei (M)

Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Seyed Mahdi Hassanian (SM)

Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Gordon A Ferns (GA)

Brighton & Sussex Medical School, Department of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.

Hanie Mahaki (H)

Vascular & Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Soodabeh Shahidsales (S)

Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: shahidsaless@mums.ac.ir.

Amir Avan (A)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq; Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia. Electronic address: avana@mums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH